[HTML][HTML] Abiraterone and increased survival in metastatic prostate cancer
…, A Molina, K Fizazi, S North… - … England Journal of …, 2011 - Mass Medical Soc
Background Biosynthesis of extragonadal androgen may contribute to the progression of
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of …
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of …
[HTML][HTML] Enzalutamide with standard first-line therapy in metastatic prostate cancer
…, R McDermott, M McJannett, SA North… - … England Journal of …, 2019 - Mass Medical Soc
Background Enzalutamide, an androgen-receptor inhibitor, has been associated with improved
overall survival in men with castration-resistant prostate cancer. It is not known whether …
overall survival in men with castration-resistant prostate cancer. It is not known whether …
[PDF][PDF] Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results …
…, BJ Eigl, JD Ruether, T Cheng, S North… - Journal of clinical …, 2009 - imdconline.com
… Sunitinib, sorafenib, and bevacizumab have been approved for use in North America and
Europe. In this era of VEGF-targeted therapies, new prognostic variables are required for …
Europe. In this era of VEGF-targeted therapies, new prognostic variables are required for …
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind …
Background Abiraterone acetate improved overall survival in metastatic castration-resistant
prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-…
prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-…
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic …
…, S Chowdhury, C Hocking, E Plas, S North… - The Lancet …, 2020 - thelancet.com
Background Survival outcomes are poor for patients with metastatic urothelial carcinoma
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …
Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy
…, GN Thalmann, T Todenhöfer, SJ Crabb, S North… - European urology, 2017 - Elsevier
Background An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC)
by gene expression suggested that response to neoadjuvant chemotherapy (NAC) …
by gene expression suggested that response to neoadjuvant chemotherapy (NAC) …
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy
…, W Xie, C Kollmannsberger, S North… - The Journal of …, 2011 - auajournals.org
Purpose : Vascular endothelial growth factor targeted therapy is a standard of care in patients
with metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the era of …
with metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the era of …
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration …
Background Bone metastases are a major cause of morbidity in metastatic castration-resistant
prostate cancer. Abiraterone acetate potently disrupts intracrine androgen receptor …
prostate cancer. Abiraterone acetate potently disrupts intracrine androgen receptor …
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
…, DP Dearnaley, CC Schulman, SA North… - Cancer, 2007 - Wiley Online Library
BACKGROUND. The objective of this study was to evaluate the efficacy and safety of
atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic …
atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic …
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy …
…, P Mainwaring, JD Hainsworth, TM Beer, S North… - European urology, 2014 - Elsevier
Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is
approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). …
approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). …
